Treatment Information

Back

Non-Hodgkin's Lymphoma treatment details. Chemotherapy, Hormone, Immunotherapy.

University Medical Center Groningen, Groningen, Netherlands.

Survival: monthsCountry:Netherlands
Toxiciy Grade:5City/State/Province:Groningen
Treatments:Chemotherapy, Hormone, ImmunotherapyHospital:University Medical Center Groningen
Drugs:Journal:Link
Date:Jul 2011

Description:

Patients:
This study involved 20 patients with T-cell lymphoma. The median patient age was 50 years and 11 were males.

Treatment:
Patients were treated with the chemotherapy agents cyclophosphamide, doxorubicin, and vincristine, the hormone prednisone, and the immune therapy agent alemtuzumab (antibody against CD52 that directs the immune system to attack cancer cells).

Toxicities:
Treatment-related deaths due to infection and pneumonia were reported.

Results:
The median overall survival was 27 months.

Support:
This study was partially supported by Bayer Schering Pharma (makers of alemtuzumab) and Genzyme.

Correspondence: Dr. H. C. Kluin-Nelemans; email: [email protected]



Back